DBV-135

DBV Technologies hopes to complete enrollment in two supplemental safety trials of a peanut allergy therapy this year. DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash. The disclosure came via a going concern note in the company’s fourth-quarter and full-year 2023 earnings report on Friday, with DBV saying it doesn’t have enough money to keep the lights on for a full 12 months. DBV says it has until the very end of the year based on the $141.4 million in cash reported as of the end of December 2023.  To persevere, the biotech will look to raise more money via debt and equity offerings. DBV’s cash reserves fell by nearly $68 million in 2023, with most of the money going toward R&D.   Much of the biotech’s focus centers on lead peanut allergy treatment DBV712, with two phase 3 safety trials ongoing in kids. The goal is to complete enrollment in two supplemental six-month safety trials this year, despite experiencing delays that were attributed to new clinical trial rules in Europe.  “We expect good momentum regarding Vitesse recruitment in the next several months and last subject screened by Q3 2024,” DBV CEO Daniel Tassé said in a release. The late-stage development work makes DBV’s current cash crunch all the more perilous, given how close the company potentially is to the market.  In addition to wrapping up enrollment in the two COMFORT trials, DBV expects to have three-year data from an efficacy trial in toddlers 1-3 years old. A sibling trial for kids 4-7 years old is slated to screen its last patient by the third quarter of 2024. That study, named VITESSE, was previously on an FDA partial hold while the company and regulators worked on an updated trial protocol.  Should DBV strengthen its balance sheet, there are two additional phase 2 trials waiting in the wings for runner-up med DBV135, which is in development for milk allergies and eosinophilic esophagitis.

Montrouge, France, March 14, 2018 DBV Technologies Reports Full Year 2017 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced full year 2017 results. Audit procedures on the Company's 2017 consolidated financial statements were completed by the Company's statutory auditors. Cash Position: cash and cash equivalents as of December 31, 2017, were €137.9 million, compared to €256.5 million as of December 31, 2016, a decrease of €118.6 million. Operating Income: operating income was €11.9 million in 2017 compared to €9.1 million in 2016, an increase of 31.1%. In 2017, income was primarily generated from the Company's Research Tax Credit (Crédit Impôt Recherche) and under the May 2016 collaboration agreement with Nestlé Health Science. Research & Development Expenses: research and development expenses increased by €26.4 million, or 33.5%, to €105.2 million in 2017, compared to €78.8 million in 2016, reflecting increased costs associated with the Phase III and Phase II clinical trials of Viaskin Peanut and Viaskin Milk, respectively, as well as a substantial increase in the number of research and development personnel employed by the Company. Sales & Marketing Expenses: sales and marketing expenses were €15.8 million for 2017 compared to €11.3 million for 2016, reflecting an increase of €4.5 million, or 40.3%. The increase in sales and marketing expenses resulted from an increase in U.S. employee headcount and expenses related to the potential launch and commercialization of Viaskin Peanut in North America, as well as an increase in share-based compensation. General & Administrative Expenses: general and administrative expenses were €35.8 million for 2017, compared to €35.0 million for 2016. The increase in general and administrative expenses was primarily attributable to an increase in personnel-related expenses as a result of our increased global employee headcount and increased costs associated with legal and professional services, partially offset by decreases in share-based compensation and insurance expenses. Net Loss: net loss was €147.7 million for 2017, compared to €114.5 million in 2016. Loss per share (based on the weighted average number of shares outstanding over the period) was €(5.97) and €(4.68) in 2017 and 2016, respectively. About DBV Technologies DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com DBV Investor Relations Contact Sara Blum Sherman Senior Director, Investor Relations & Strategy +1 212-271-0740 sara.sherman@dbv-technologies.com DBV Media Contact Roberta Di Giorgio Senior Director, Corporate Communications +1 917-612-2861 roberta.digiorgio@dbv-technologies.com